AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2022 and recent updates. Second Quarter Fiscal Year 2023 and Subsequent Highlights: Completed dosing its randomized, double-blind, placebo-controlled Phase 2 trial evalua
About Business Wire
